Endonovo Therapeutics, Inc. financial data

Symbol
ENDV on OTC
Location
6320 Canoga Avenue, 15 Th Floor, Woodland Hills, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Hanover Portfolio Acquisitions, Inc. (to 1/24/2014)
Latest financial report
10-Q/A - Q3 2023 - Dec 29, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 0.21 % -12.5%
Debt-to-equity -104 % +4.97%
Return On Equity 17.3 % -0.35%
Return On Assets -409 % -123%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 319M shares +64%
Common Stock, Shares, Outstanding 319M shares +100%
Entity Public Float 1.13M USD -51%
Common Stock, Value, Issued 27.9K USD +75.5%
Weighted Average Number of Shares Outstanding, Basic 298M shares +94.3%
Weighted Average Number of Shares Outstanding, Diluted 1.35B shares +779%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 256K USD +1700%
Cost of Revenue 827 USD -79.5%
Operating Income (Loss) -2.62M USD +17.1%
Nonoperating Income (Expense) -1.79M USD -20618%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -4.4M USD -40%
Net Income (Loss) Attributable to Parent -4.4M USD -40%
Earnings Per Share, Basic -0.05 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 0 USD -100%
Accounts Receivable, after Allowance for Credit Loss, Current 3.12K USD +230%
Assets, Current 35.5K USD +47.4%
Assets 816K USD -43.8%
Accounts Payable, Current 884K USD +34.3%
Liabilities, Current 23.7M USD +13%
Other Liabilities, Noncurrent 79.8K USD 0%
Liabilities 23.8M USD +12.9%
Retained Earnings (Accumulated Deficit) -66.6M USD -7.49%
Stockholders' Equity Attributable to Parent -23M USD -17.1%
Liabilities and Equity 816K USD -43.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -173K USD -40.8%
Net Cash Provided by (Used in) Financing Activities 184K USD +89.7%
Common Stock, Shares Authorized 2.5B shares 0%
Common Stock, Shares, Issued 319M shares +100%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 10.8K USD
Additional Paid in Capital 43.6M USD +3.02%
Amortization of Intangible Assets 162K USD 0%
Depreciation, Depletion and Amortization 162K USD -0.97%